Pacific Biosciences of California, Inc. (PACB)
PACB Stock Price Chart
Explore Pacific Biosciences of California, Inc. interactive price chart. Choose custom timeframes to analyze PACB price movements and trends.
PACB Company Profile
Discover essential business fundamentals and corporate details for Pacific Biosciences of California, Inc. (PACB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
27 Oct 2010
Employees
575.00
Website
https://www.pacb.comCEO
Christian O. Henry
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
PACB Financial Timeline
Browse a chronological timeline of Pacific Biosciences of California, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 9 Feb 2027
Upcoming earnings on 3 Nov 2026
Upcoming earnings on 3 Aug 2026
Upcoming earnings on 7 Apr 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.16, while revenue estimate is $40.25M.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.18 by +27.78%, while revenue for the quarter reached $39.77M , missing expectations by -0.46%.
Earnings released on 8 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $37.15M , beating expectations by +0.69%.
Earnings released on 13 Feb 2025
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $39.22M , missing expectations by -3.58%.
Earnings released on 7 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%, while revenue for the quarter reached $39.97M , missing expectations by -4.73%.
Earnings released on 7 Aug 2024
EPS came in at -$0.20 surpassing the estimated -$0.24 by +16.67%, while revenue for the quarter reached $36.01M , missing expectations by -11.91%.
Earnings released on 9 May 2024
EPS came in at -$0.26 matching the estimated -$0.26, while revenue for the quarter reached $38.81M , missing expectations by -10.66%.
Earnings released on 15 Feb 2024
EPS came in at -$0.27 surpassing the estimated -$0.31 by +12.90%, while revenue for the quarter reached $58.36M , beating expectations by +1.51%.
Earnings released on 30 Oct 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%, while revenue for the quarter reached $55.69M , beating expectations by +14.21%.
Earnings released on 2 Aug 2023
EPS came in at -$0.26 surpassing the estimated -$0.34 by +23.53%, while revenue for the quarter reached $47.57M , beating expectations by +18.05%.
Earnings released on 2 May 2023
EPS came in at -$0.31 surpassing the estimated -$0.33 by +6.06%, while revenue for the quarter reached $38.90M , beating expectations by +13.15%.
Earnings released on 16 Feb 2023
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $27.35M , beating expectations by +4.39%.
Earnings released on 7 Nov 2022
EPS came in at -$0.32 surpassing the estimated -$0.35 by +8.57%, while revenue for the quarter reached $32.31M , missing expectations by -8.73%.
Earnings released on 3 Aug 2022
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $35.47M , beating expectations by +0.87%.
Earnings released on 4 May 2022
EPS came in at -$0.37 falling short of the estimated -$0.32 by -15.62%, while revenue for the quarter reached $33.17M , beating expectations by +0.79%.
Earnings released on 15 Feb 2022
EPS came in at -$0.30 falling short of the estimated -$0.28 by -7.14%, while revenue for the quarter reached $36.02M , missing expectations by -0.28%.
Earnings released on 2 Nov 2021
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $34.89M , beating expectations by +5.08%.
Earnings released on 3 Aug 2021
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $30.61M , beating expectations by +2.07%.
Earnings released on 29 Apr 2021
EPS came in at -$0.18 surpassing the estimated -$0.45 by +60.00%, while revenue for the quarter reached $29.00M , beating expectations by +12.96%.
Earnings released on 10 Feb 2021
EPS came in at -$0.01 falling short of the estimated $0.43 by -102.33%, while revenue for the quarter reached $27.14M , beating expectations by +18.52%.
Earnings released on 2 Nov 2020
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $19.08M , beating expectations by +7.69%.
PACB Stock Performance
Access detailed PACB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.